GROUPE FRANCOPHONE DES MYELODYSPLASIES

🇫🇷France

Country: 🇫🇷France

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response

Phase 2

Completed

Conditions: MDS

Interventions: Drug: SGI-110 administration

First Posted Date: 2014-07-23

Last Posted Date: 2018-12-06

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 56

Registration Number: NCT02197676

Locations: 🇫🇷
Hopital Purpan Service d'Hématologie Clinique, Toulouse, France
🇫🇷
CHU Brabois, Vandœuvre-lès-Nancy, France
🇫🇷
CH Angers, Angers, France

and more 24 locations

GFM-Acadesine: A Phase I-II Trial of Acadesine

Phase 1

Terminated

Conditions: SMD

Interventions: Drug: ACADESINE 210mg/kg/d
Drug: ACADESINE 140mg/kg/d
Drug: ACADESINE 315mg/kg/d

First Posted Date: 2013-03-19

Last Posted Date: 2016-11-08

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 5

Registration Number: NCT01813838

Locations: 🇫🇷
CHU de Grenoble, Grenoble, France
🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷
Centre hospitalier de la côte Basque, Bayonne, France

and more 14 locations

Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Azacitidine and oral vorinostat

First Posted Date: 2012-12-12

Last Posted Date: 2019-06-04

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 21

Registration Number: NCT01748240

Locations: 🇫🇷
CHU de Grenoble, Grenoble, France
🇫🇷
CHU d'Angers, Angers, France
🇫🇷
CH Annecy, Annecy, France

and more 21 locations

A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS

Phase 1

Conditions: MDS

Interventions: Drug: Deferasirox, Vitamin D and Azacitidine

First Posted Date: 2012-10-31

Last Posted Date: 2018-01-10

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 50

Registration Number: NCT01718366

Locations: 🇫🇷
CHU Limoges, Limoges, France
🇧🇪
GENT, Gent, Belgium
🇫🇷
Hôpital Avicenne, Bobigny, France

and more 12 locations

Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.

Phase 2

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Lenalidomide
Drug: Epoetin beta

First Posted Date: 2012-10-31

Last Posted Date: 2016-11-08

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 132

Registration Number: NCT01718379

Locations: 🇲🇨
centre hopitalier princesse Grace, Monaco, Monaco
🇫🇷
Hopital Saint Antoine, Paris, France
🇫🇷
CH de la Cote Basque, Bayonne, France

and more 45 locations

Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes

Phase 1

Withdrawn

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Ceplene®, IL-2, Azacitidine
Drug: Azacitidine

First Posted Date: 2011-03-29

Last Posted Date: 2014-03-20

Lead Sponsor: Groupe Francophone des Myelodysplasies

Registration Number: NCT01324960

Locations: 🇫🇷
CHU Cochin, Paris, Ile de France, France
🇫🇷
CHU Grenoble, Grenoble, France
🇫🇷
Hôpital Versailles, Le Chesnay, France

and more 25 locations

Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes

Phase 1

Completed

Conditions: High Grade Myelodysplastic Syndrome Lesions

Interventions: Drug: azacitidine and idarubicin

First Posted Date: 2011-02-28

Last Posted Date: 2017-06-07

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 41

Registration Number: NCT01305135

Locations: 🇫🇷
CHU Dijon Hôpital d'enfants, Dijon, France
🇫🇷
CHU Albert Michallon, Grenoble, France
🇫🇷
Hôpital Hautepierre, Strasbourg, France

and more 29 locations

Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)

Phase 1

Completed

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Azacitidine

First Posted Date: 2011-02-28

Last Posted Date: 2021-12-28

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 27

Registration Number: NCT01305460

Locations: 🇫🇷
CHU d'Amiens, Amiens, France
🇫🇷
Centre henri Mondor, Creteil, France
🇫🇷
Centre Hospitalier de La Cote Basque, Bayonne, France

and more 18 locations

Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)

Phase 2

Completed

Conditions: Chronic Myelomonocytic Leukemia

Interventions: Drug: Decitabine

First Posted Date: 2010-04-02

Last Posted Date: 2014-03-20

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 41

Registration Number: NCT01098084

Locations: 🇫🇷
CH Angers, Angers, France
🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷
CHU de Bicêtre, Le Kremlin-Bicêtre, Ile de France, France

and more 28 locations

Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q

Phase 2

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Azacitidine combined to Lenalidomide

First Posted Date: 2010-03-17

Last Posted Date: 2017-12-15

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 50

Registration Number: NCT01088373

Locations: 🇫🇷
Hôpital la pitié-Salpétrière, Paris, France
🇫🇷
CHU Bretonneau, Tours, France
🇫🇷
Hôpital PURPAN, Service d'Hématologie Clinique, Toulouse, France

and more 31 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy